# KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)

Study · id `cardio:ct-nct03236246` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03236246](<https://clinicaltrials.gov/study/NCT03236246>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03236246

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 206 participants.

## Technical summary

Registry record NCT03236246. Randomized; no masking; primary purpose treatment. Start 2017-08-15 (actual); primary completion 2019-08-30 (actual). Results posted on 2021-03-12.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 206 participants (enrolled count; ClinicalTrials.gov record NCT03236246, source copy `cardio:ctgov-nct03236246-2021-03-12`, retrieved 2026-10-26)
- Started: 2017-08-15 (actual) (ClinicalTrials.gov record NCT03236246, source copy `cardio:ctgov-nct03236246-2021-03-12`, retrieved 2026-10-26)
- Primary completion: 2019-08-30 (actual) (ClinicalTrials.gov record NCT03236246, source copy `cardio:ctgov-nct03236246-2021-03-12`, retrieved 2026-10-26)
- Completion: 2019-09-27 (actual) (ClinicalTrials.gov record NCT03236246, source copy `cardio:ctgov-nct03236246-2021-03-12`, retrieved 2026-10-26)
- Results first posted: 2021-03-12 (ClinicalTrials.gov record NCT03236246, source copy `cardio:ctgov-nct03236246-2021-03-12`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03236246, source copy `cardio:ctgov-nct03236246-2021-03-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03236246-2021-03-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)
- Acronym: COMPASS
- Condition: Chronic Kidney Diseases
- Condition: Iron Deficiency Anemia
- Intervention (Drug): KRX-0502
- Lead sponsor: Keryx Biopharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Keryx Biopharmaceuticals (`cardio:org-keryx-biopharmaceuticals`)

## Provenance

Content hash: 2e1e045e6b033486124e55ecc8fcafd79b2c9e8aa37e4b3cfc1c0bf690d8b789
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
